Chinese Journal of Tissue Engineering Research ›› 2022, Vol. 26 ›› Issue (34): 5442-5447.doi: 10.12307/2022.453

Previous Articles     Next Articles

Hemostatic effect of macroporous polysaccharides composite hemostatic materials on small-artery severed injury

Xu Lin1, 2, Cheng Gangyi3, Li Hongwei1, 2, Wang Hongjian1, 4, Lin Minghui3, Guo Hongwei3, Lin Lianfeng3, Xu Ling1, 2   

  1. 1Translational Medicine Research of Biomaterial, School of Public Health, Xiamen University, Xiamen 361102, Fujian Province, China; 2National Institute of Diagnostics and Vaccine Development in Infectious Disease, Xiamen University, Xiamen 361102, Fujian Province, China; 3First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China; 4Xiamen Gelfeel Biological Technology Co., Ltd., Xiamen 361028, Fujian Province, China
  • Received:2021-03-05 Accepted:2021-04-15 Online:2022-12-08 Published:2022-04-15
  • Contact: Xu Ling, PhD, Professor, Translational Medicine Research of Biomaterial, School of Public Health, Xiamen University, Xiamen 361102, Fujian Province, China; National Institute of Diagnostics and Vaccine Development in Infectious Disease, Xiamen University, Xiamen 361102, Fujian Province, China
  • About author:Xu Lin, Master, Translational Medicine Research of Biomaterial, School of Public Health, Xiamen University, Xiamen 361102, Fujian Province, China; National Institute of Diagnostics and Vaccine Development in Infectious Disease, Xiamen University, Xiamen 361102, Fujian Province, China Cheng Gangyi, Master, Physician, First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China Xu Lin and Cheng Gangyi contributed equally to this article.
  • Supported by:
    Fujian Marine Economy Development Subsidy Fund Project, No. FJHJF-L-2019-4 (to XL)

Abstract: BACKGROUND: The hemostatic performance of absorbable hemostatic materials for arterial bleeding cannot meets for the clinical demands. 
OBJECTIVE: To study the hemostatic effect of macroporous polysaccharides composite hemostatic materials on small artery hemorrhage. 
METHODS: The rabbit model of arteriolar hemorrhage was established by severing the femoral artery and randomly divided into two groups. The experimental group (n=10) was treated with macroporous polysaccharides composite hemostatic materials, and the control group (n=7) was treated with commercial microporous polysaccharide hemostatic powder. After operation, hemostatic success rate, blood loss, blood routine test, liver and kidney function index were recorded and hematoxylin-eosin staining was used to observe wound tissue. 
RESULTS AND CONCLUSION: (1) The success ratio of hemostasis in experimental group was higher than that in the control group (90%, 43%, P < 0.05). There was no significant difference in intraoperative blood loss between the two groups (P > 0.05). (2) The blood routine and liver and kidney function index test results within 180 days after operation showed that the change trend of each index of the two groups was basically the same, and the two hemostatic materials did not cause obvious liver and kidney dysfunction, nor did it cause purulent or inflammation in the degradation and absorption process. (3) The hematoxylin-red staining of the wound tissue 90 days after the operation showed that the tissues in the experimental group were evenly stained; the muscle fiber morphology and structure were normal; the boundaries were clear; and the arrangement was regular. There was no obvious abnormality in the interstitium, and no scars in the wound. In the control group, the tissues were uniformly stained; the morphology and structure of muscle fibers were normal; the boundaries were clear; and the arrangement was regular. There was no obvious abnormality in the interstitium, but there were more scars locally. (4) These results suggest that effectiveness of the macroporous polysaccharides composite hemostatic materials is higher than that of the commercial hemostatic powder. The safety is not inferior to that of the commercial hemostatic powder. Therefore, the macroporous polysaccharides composite hemostatic materials can be used for hemostasis in vivo.

Key words: composite macroporous polysaccharide hemostatic material, composite microporous polysaccharide hemostatic powder, carboxymethyl chitosan, absorbable hemostatic material, small arterial hemostasis, arterial disconnection

CLC Number: